Cancer Dependency Map Analytics | Cancer, Ageing and Somatic Mutation
Our Research and Approach
We design algorithms and computational tools for the analysis of large-scale cancer pharmacogenomics and functional genomics datasets (from chemical and genome-editing screens) to the aim of identifiying new oncology therapeutic targets and markers of gene-essentiality/drug-response.
In partnership with Open Targets, we provide computational support and analytic solutions to the international Cancer Dependency Map consortium, and to other projects engaged in the analysis of data from large-scale chemo/genetic screens.
We are recruiting: We are currently seeking for a senior bioinformatician (Job Ref. 83193). Contact email@example.com for informal enquiries.
Francesco completed his PhD in the Systems, Synthetic and Computational Biology Laboratory of the TeleThon Institute of Genetics and Medicine (TIGEM, Naples, Italy), focusing on computational methods for drug discovery and repositioning based on the analysis of large compendia of gene expression profiles. Subsequently he was awarded a joint EMBL-EBI/Sanger postdoctoral fellowship (ESPOD) and he worked on integrative computational frameworks for predicting and dissecting drug susceptibility in cancer based on the analysis of data from large-scale drug screens. Prior joining CASM at the Wellcome Sanger Institute, he has been the leading computational scientist in a project funded by Open Targets aiming at identifying new therapeutic targets and synthetic lethalities in cancer, through the analysis of data from a large-scale, genome-wide CRISPR-Cas9 knockout screen across hundreds of cancer cell lines.
Open Targets Postdoctoral Fellow
Key Projects, Collaborations, Tools & Data
Research Programmes and Faciltites
Partners and Funders
External Partners and Funders
Open Targets is a pioneering public-private partnership between Biogen, Celgene, EMBL-EBI, GlaxoSmithKline (GSK), Takeda, and the Wellcome Sanger Institute and is located on the Wellcome Genome Campus. Open Targets brings together expertise from six complementary institutions to systematically identify and prioritise targets from which safe and effective medicines can be developed, to help others find good targets, and to get those targets adopted into drug discovery pipelines.
Current focuses are oncology, immunology and neurodegeneration through an R&D framework that can be applied to all aspects of human disease.